Introduction
Alpha-Lipoic Acid (ALA) is one of the most widely studied and used ingredients in modern nutraceutical formulations thanks to its role in cellular energy metabolism and antioxidant activity. Its applications are well established in metabolic support, neurological wellness, healthy aging, and sports nutrition.
However, the intrinsic characteristics of ALA may limit formulation performance and consumer acceptance. In particular, its characteristic taste, potential gastric sensitivity, and rapid release profile represent significant formulation challenges.
To address these limitations, IPS has developed ALA MATRIS® FAST and ALA MATRIS® RETARD, two solutions based on proprietary and patented MATRIS® technology, designed to provide effective taste masking and different release profiles according to formulation needs.
Properties and application fields of Alpha-Lipoic Acid
ALA is an essential cofactor involved in cellular energy processes and is widely used in nutraceutical applications:
• Metabolic support
Involved in cellular energy metabolism.
• Antioxidant activity
Supports physiological defense systems against oxidative stress.
• Neurological support
Used in formulations dedicated to neuronal metabolism.
• Healthy aging
Frequently included in wellness and active-aging formulations.
Formulation challenges of Alpha-Lipoic Acid
Despite its broad use, ALA presents several limitations:
• Characteristic taste and odor, affecting sensory acceptance
• Potential gastric sensitivity in susceptible individuals
• Rapid release, limiting prolonged gastrointestinal availability
• Challenges in developing advanced high-load formulations
These aspects highlight the need for a technological approach capable of improving user experience and optimizing active-ingredient performance.
IPS innovation: ALA MATRIS® FAST and ALA MATRIS® RETARD
IPS has developed two complementary microencapsulated Alpha-Lipoic Acid solutions through proprietary and patented MATRIS® technology.
Designed for applications requiring immediate active availability, it provides:
• Effective taste masking
• Improved sensory acceptance
• Better tolerability compared to conventional ALA
• High formulation versatility
Developed for applications requiring extended active availability, it provides:
• Effective taste masking
• Prolonged release up to 8 hours
• Improved intestinal bioaccessibility
• Reduced gastric sensitivity
• Support for continuous-release formulations
In both versions, the coating system is designed to modulate release without altering the nature of the active ingredient.
Scientific evidence
Direct preclinical evidence is available for Alpha-Lipoic Acid MATRIS®.
Advanced in vitro 3D studies conducted on human intestinal, gastric, and neuronal organoids compared raw ALA with MATRIS®-formulated ALA.
The results demonstrated:
• more gradual and modulated release of ALA MATRIS®
• improved interaction with the intestinal epithelium
• reduced impact on gastric and intestinal membranes
• improved tolerability profile
• greater effectiveness on the peripheral nervous system
These findings confirm that the observed benefits are directly attributable to MATRIS® technology, which represents the determining factor in the behavior of the microencapsulated active ingredient.
Formulations and applications
ALA MATRIS® FAST and ALA MATRIS® RETARD are suitable for:
• capsules
• tablets
• sachets and stick packs
• dosing-cap vials
• SmarTTabs®, technological innovation by IPS for direct compression, preserving the release profile
This versatility enables the development of customized formulations for different market and consumer needs.
Conclusion
Alpha-Lipoic Acid is a benchmark ingredient in modern nutraceuticals, but its sensory and formulation characteristics require advanced technological solutions.
With ALA MATRIS® FAST and ALA MATRIS® RETARD, IPS offers two complementary approaches combining taste masking, improved tolerability, and differentiated release profiles, allowing formulators to select the most suitable solution for their applications.
The MATRIS® technology further confirms the role of the SURACTIVES® division of IPS as a technology provider in the development of high-performance nutraceutical ingredients.
Note: This article is provided for informational purposes only and does not substitute professional medical advice.
